Deals Shaping The Medical Industry, July 2015
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2015.
You may also be interested in...
Arcturus's Differentiated RNA Technology Faces First Clinical Test In 2017
Emerging Company Profile: San Diego-based Arcturus Therapeutics has developed technology for the targeted delivery of RNA therapeutics, which Johnson & Johnson's Janssen subsidiary will evaluate for the first time in humans in a clinical trial starting as early as this year for the partners' hepatitis B drug candidate.
Gilead Keeps Focus On HIV, Long-Acting Drugs And Growth Through Oncology
Even with top-seller Biktarvy and its preventive therapy, Descovy, protected beyond this decade from generics, Gilead is investing aggressively in long-acting HIV candidates and its oncology pipeline.
Talking Trials, Investment And Fluid-Overload Treatments With Sequana Medical
Sequana Medical is simultaneously developing both drug and device treatments for fluid overloads in the body. Medtech Insight spoke to the company’s CEO about their trials and the challenges of raising cash in 2023.